Swiss pharmaceutical major Roche has announced a significant investment plan for India, pledging 1.5 billion Swiss francs (around $1.9 billion) over the next five years. The move reflects the company’s growing confidence in India not only as a key market but also as an important hub for innovation and research.
The planned investment will focus on strengthening Roche’s core business operations in India, expanding research and development, and enhancing access to innovative healthcare solutions. The company, which already employs more than 5,000 people in the country, said the fresh commitment underscores its long-term vision to contribute to India’s evolving healthcare ecosystem.
Roche has also indicated plans to collaborate with national health initiatives such as Ayushman Bharat to make advanced therapies more accessible to patients across the country. By working closely with the government and healthcare providers, the company aims to strengthen public-private partnerships that can improve treatment outcomes.
This announcement comes at a time when India’s trade agreement with the European Free Trade Association (EFTA) is opening new avenues for foreign investment. Roche’s pledge is seen as part of a broader wave of interest from Swiss and other EFTA-region companies seeking to expand their footprint in India under the new trade and investment frameworks.